Ishara Investments LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Ishara Investments LP reported 41 stock positions worth $136.1 million. Its top holding was Acadia Pharmaceuticals (ACAD) at 7.6% of the portfolio, followed by Xeris Biopharma (XERS, 7.2%) and Biomarin Pharmaceutical (BMRN, 6.0%). Compared with Q1 2026, it opened 16 new positions, sold out of 11, added to 13 and reduced 8. The biggest buy was Acadia Pharmaceuticals (ACAD, shares +233%) and the biggest sale an exit from Kalvista Pharmaceuticals (KALV).
- Most Recent 13F
- Q2 2026
- Location
- LOS ANGELES, CA
- CIK
- 0002111609
- Portfolio Value
- $136.1M (Q2 2026)
- SEC Filing
- 0002111609-26-000004 ↗ filed Aug 14, 2026
Holdings Value
Holdings 41 stocks · $136.1M
| ACAD Acadia Pharmaceuticals Inc. | 7.62% | 410,000 | $10.4M | Add +233.3% |
| XERS Xeris Biopharma Holdings Inc. | 7.16% | 1,230,000 | $9.7M | Add +20.0% |
| BMRN Biomarin Pharmaceutical Inc. | 6.03% | 143,500 | $8.2M | Add +75.0% |
| PRAX Praxis Precision Medicines I | 5.55% | 22,550 | $7.5M | No change |
| RARE Ultragenyx Pharmaceutical Inc. | 5.03% | 205,000 | $6.8M | Add +17.6% |
| AGIO Agios Pharmaceuticals Inc. | 4.47% | 164,000 | $6.1M | New |
| INSM Insmed Inc. | 4.01% | 51,250 | $5.5M | New |
| CRNX Crinetics Pharmaceuticals Inc. | 3.95% | 143,500 | $5.4M | New |
| ZNTL Zentalis Pharmaceuticals Inc. | 3.65% | 1,025,000 | $5.0M | Reduce -16.7% |
| PCVX Vaxcyte Inc. | 3.50% | 82,000 | $4.8M | Add +42.9% |
| ANNX Annexon Inc. | 3.44% | 820,000 | $4.7M | Add +370.6% |
| TVTX Travere Therapeutics Inc. | 3.42% | 82,000 | $4.7M | Reduce -25.9% |
| TNXP Tonix Pharmaceuticals Holdin | 3.17% | 338,250 | $4.3M | New |
| BBIO Bridgebio Pharma Inc. | 3.14% | 57,400 | $4.3M | New |
| AXSM Axsome Therapeutics Inc. | 2.95% | 16,400 | $4.0M | Reduce -60.0% |
| CTNM Contineum Therapeutics Inc. Class A | 2.47% | 205,000 | $3.4M | Add +44.4% |
| LXRX Lexicon Pharmaceuticals Inc. | 2.24% | 1,271,000 | $3.1M | Add +40.9% |
| KURA Kura Oncology Inc. | 2.23% | 276,750 | $3.0M | New |
| DBVT DBV Technologies SA-Spon ADR | 2.22% | 184,500 | $3.0M | Add +80.0% |
| GMAB Genmab A/S -SP ADR | 2.07% | 102,500 | $2.8M | Add +25.0% |
| CYTK Cytokinetics Inc. | 2.05% | 32,800 | $2.8M | New |
| MLYS Mineralys Therapeutics Inc. | 2.03% | 102,500 | $2.8M | Add +25.0% |
| SLN Silence Therapeutics PLC-ADR | 1.79% | 55,350 | $2.4M | Reduce -60.6% |
| NUVB Nuvation Bio Inc. | 1.54% | 369,000 | $2.1M | New |
| WVE Wave Life Sciences Ltd. | 1.40% | 328,000 | $1.9M | New |
| NKTR Nektar Therapeutics | 1.37% | 26,650 | $1.9M | New |
| SRRK Scholar Rock Holding Corp. | 1.24% | 30,750 | $1.7M | Reduce -46.4% |
| ELVN Enliven Therapeutics Inc. | 1.22% | 32,800 | $1.7M | New |
| ALNY Alnylam Pharmaceuticals Inc. | 1.13% | 5,125 | $1.5M | No change |
| BEAM Beam Therapeutics Inc. | 1.03% | 41,000 | $1.4M | Reduce -28.6% |
| SION Sionna Therapeutics Inc. | 0.99% | 123,000 | $1.4M | Add +150.0% |
| ORIC Oric Pharmaceuticals Inc. | 0.98% | 123,000 | $1.3M | Add +20.0% |
| NAMS Newamsterdam Pharma Co. NV | 0.92% | 36,900 | $1.3M | No change |
| VRTX Vertex Pharmaceuticals Inc. | 0.90% | 2,460 | $1.2M | New |
| SPRY Ars Pharmaceuticals Inc. | 0.84% | 143,490 | $1.1M | New |
| MNPR Monopar Therapeutics Inc. | 0.84% | 12,300 | $1.1M | New |
| ERAS Erasca Inc. | 0.55% | 41,000 | $751K | New |
| VERA Vera Therapeutics Inc. | 0.32% | 10,250 | $440K | Reduce -87.5% |
| IMTX Immatics NV | 0.23% | 30,750 | $311K | Reduce -80.0% |
| MREO Mereo Biopharma Group PL-ADR | 0.18% | 768,750 | $244K | New |
| GOSS Gossamer Bio Inc. | 0.10% | 820,000 | $135K | No change |
Portfolio Sells Q1 2026 → Q2 2026
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −5.63 |
| FOLD Amicus Therapeutics Inc. | Sold out | 0.00% | −5.39 |
| VSTM Verastem Inc. | Sold out | 0.00% | −4.39 |
| AXSM Axsome Therapeutics Inc. | Reduce -60.0% | 2.95% | −4.05 |
| ARWR Arrowhead Pharmaceuticals Inc. | Sold out | 0.00% | −3.50 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −3.28 |
| VERA Vera Therapeutics Inc. | Reduce -87.5% | 0.32% | −3.01 |
| ARDX Ardelyx Inc. | Sold out | 0.00% | −2.73 |
| CPRX Catalyst Pharmaceuticals Inc. | Sold out | 0.00% | −2.05 |
| LGND Ligand Pharmaceuticals | Sold out | 0.00% | −1.65 |
| SRRK Scholar Rock Holding Corp. | Reduce -46.4% | 1.24% | −1.61 |
| EWTX Edgewise Therapeutics Inc. | Sold out | 0.00% | −1.57 |
| IMTX Immatics NV | Reduce -80.0% | 0.23% | −1.30 |
| IDYA Ideaya Biosciences Inc. | Sold out | 0.00% | −0.83 |
| PTCT PTC Therapeutics Inc. | Sold out | 0.00% | −0.71 |
| BEAM Beam Therapeutics Inc. | Reduce -28.6% | 1.03% | −0.35 |
| TVTX Travere Therapeutics Inc. | Reduce -25.9% | 3.42% | +0.10 |
| ZNTL Zentalis Pharmaceuticals Inc. | Reduce -16.7% | 3.65% | +0.75 |
| SLN Silence Therapeutics PLC-ADR | Reduce -60.6% | 1.79% | +1.04 |
Portfolio Buys Q1 2026 → Q2 2026
| ACAD Acadia Pharmaceuticals Inc. | Add +233.3% | 7.62% | +4.86 |
| AGIO Agios Pharmaceuticals Inc. | New | 4.47% | +4.47 |
| INSM Insmed Inc. | New | 4.01% | +4.01 |
| CRNX Crinetics Pharmaceuticals Inc. | New | 3.95% | +3.95 |
| TNXP Tonix Pharmaceuticals Holdin | New | 3.17% | +3.17 |
| BBIO Bridgebio Pharma Inc. | New | 3.14% | +3.14 |
| ANNX Annexon Inc. | Add +370.6% | 3.44% | +2.47 |
| KURA Kura Oncology Inc. | New | 2.23% | +2.23 |
| CYTK Cytokinetics Inc. | New | 2.05% | +2.05 |
| NUVB Nuvation Bio Inc. | New | 1.54% | +1.54 |
| WVE Wave Life Sciences Ltd. | New | 1.40% | +1.40 |
| NKTR Nektar Therapeutics | New | 1.37% | +1.37 |
| BMRN Biomarin Pharmaceutical Inc. | Add +75.0% | 6.03% | +1.36 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +17.6% | 5.03% | +1.34 |
| ELVN Enliven Therapeutics Inc. | New | 1.22% | +1.22 |
| XERS Xeris Biopharma Holdings Inc. | Add +20.0% | 7.16% | +1.15 |
| VRTX Vertex Pharmaceuticals Inc. | New | 0.90% | +0.90 |
| SPRY Ars Pharmaceuticals Inc. | New | 0.84% | +0.84 |
| MNPR Monopar Therapeutics Inc. | New | 0.84% | +0.84 |
| LXRX Lexicon Pharmaceuticals Inc. | Add +40.9% | 2.24% | +0.82 |
| CTNM Contineum Therapeutics Inc. Class A | Add +44.4% | 2.47% | +0.60 |
| ERAS Erasca Inc. | New | 0.55% | +0.55 |
| MREO Mereo Biopharma Group PL-ADR | New | 0.18% | +0.18 |
| PCVX Vaxcyte Inc. | Add +42.9% | 3.50% | +0.13 |
| DBVT DBV Technologies SA-Spon ADR | Add +80.0% | 2.22% | +0.06 |
| GMAB Genmab A/S -SP ADR | Add +25.0% | 2.07% | −0.15 |
| MLYS Mineralys Therapeutics Inc. | Add +25.0% | 2.03% | −0.21 |
| ORIC Oric Pharmaceuticals Inc. | Add +20.0% | 0.98% | −0.33 |
| SION Sionna Therapeutics Inc. | Add +150.0% | 0.99% | −1.00 |
Options Activity Q1 2026 → Q2 2026
| PRAX Praxis Precision Medicines I | put | Sold out | 20,500 | $6.6Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.